Alk-Abelló A/S, of Copenhagen, said that its partner Torii Pharmaceutical Co. Ltd., of Tokyo, gained approval from the Japanese Ministry of Health, Labour and Welfare to expand the use of Miticure, a sublingual allergy immunotherapy tablet, to include treating pediatric allergic rhinitis patients.